Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Imetelstat's Promise | Geron's lead product shows efficacy in treating myelodysplastic syndromes and myelofibrosis, positioning the company as a potential key player in oncology |
Financial Trajectory | Analysts project 311.66% revenue growth for FY2024 and potential profitability by H2 2025, despite current negative earnings |
Market Dynamics | Explore Geron's commercial launch of Rytelo and its strategic IP approach, potentially securing market exclusivity beyond 2035 |
Growth Horizons | Analysts maintain a bullish consensus with an average price target of $9.00, citing label expansion potential and strong revenue projections |
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.3x | −3.1x | −0.6x | |
PEG Ratio | −1.59 | −0.15 | 0.00 | |
Price/Book | 5.7x | 1.3x | 2.6x | |
Price / LTM Sales | 56.9x | 42.3x | 3.1x | |
Upside (Analyst Target) | 183.7% | 216.4% | 48.7% | |
Fair Value Upside | Unlock | 23.3% | 7.7% | Unlock |